Addiction is not a fringe problem. It is one of the most widespread and underfunded public health crises in the United States. The numbers below — drawn from SAMHSA's National Survey on Drug Use and Health, the CDC's National Center for Health Statistics, and the National Institute on Drug Abuse — paint a picture that should be impossible to ignore. And yet, year after year, the gap between the scope of the problem and the scale of the response keeps growing.
This is the 2026 landscape. These are the numbers that define it.
The Big Picture: Prevalence of Substance Use Disorders
According to SAMHSA's most recent National Survey on Drug Use and Health, 46.3 million Americans aged 12 and older met the diagnostic criteria for a substance use disorder (SUD) in the past year. That is roughly one in every seven people in the country — more than the populations of New York, Los Angeles, Chicago, Houston, and Phoenix combined.
Of those 46.3 million, 29.5 million had an alcohol use disorder (AUD), making alcohol the single most prevalent substance of misuse in the United States by a wide margin. And the consequences are not abstract. The CDC reports that over 107,000 Americans died from drug overdoses in the most recent 12-month reporting period — a number that has plateaued at historically catastrophic levels after years of relentless escalation.
These are not edge cases. These are your coworkers, your neighbors, your family members. Addiction does not discriminate by income, education, or zip code.
Alcohol: The Normalized Epidemic
Alcohol occupies a unique position in the addiction landscape because it is the one substance our culture actively encourages people to consume. Happy hours, wine culture, craft beer snobbery, bottomless brunch — alcohol is woven so deeply into social life that questioning your relationship with it feels countercultural.
The data tells a different story than the marketing.
SAMHSA estimates that 14.5 million adults in the United States have an alcohol use disorder, representing approximately 6.4 percent of the adult population. Binge drinking — defined as consuming four or more drinks for women or five or more for men on a single occasion — is reported by 22 percent of American adults, or roughly 61 million people.
The economic toll is staggering. The CDC estimates that excessive alcohol use costs the United States approximately $249 billion per year in lost workplace productivity, healthcare expenses, law enforcement costs, and motor vehicle crashes. That works out to about $2.05 per drink consumed — a tab that falls on everyone, not just drinkers.
And yet alcohol remains the substance most likely to be dismissed as "not a real problem." If you have ever been told you are overreacting for questioning someone's drinking — or your own — you are not alone, and you are not wrong.
Opioids: The Crisis That Will Not End
The opioid epidemic has entered its fourth wave, and this one is defined by synthetic opioids — primarily illicitly manufactured fentanyl. NIDA reports that approximately 2.7 million Americans have an opioid use disorder (OUD), but that number almost certainly undercounts the reality. Many people with OUD never engage with the healthcare system and never appear in survey data.
The mortality numbers are less ambiguous. Fentanyl is now involved in over 70 percent of all overdose deaths in the United States. Its potency — roughly 50 to 100 times stronger than morphine — means that the margin between a dose and a lethal dose is vanishingly thin. People who believe they are using cocaine, counterfeit pills, or even marijuana have died from fentanyl contamination.
The prescription-to-street pipeline remains a core driver of the crisis. Many people with OUD began with a legitimate prescription for pain — post-surgery, post-injury, post-dental procedure. When the prescription ran out or was cut off, the street supply was waiting. The pharmaceutical industry's aggressive marketing of OxyContin in the late 1990s and 2000s created a generation of patients whose pain management became dependency, and whose dependency was met with abandonment rather than treatment.
This is not a moral failure. It is a systems failure. And the numbers make that clear.
Marijuana: Legalization and the Addiction Question
Marijuana occupies an increasingly complicated space in the addiction conversation. As legalization has spread — now encompassing the majority of US states in some form — the cultural narrative has shifted toward treating cannabis as essentially harmless. The clinical data is more nuanced.
SAMHSA estimates that 16.3 million Americans meet the criteria for cannabis use disorder (CUD). That does not mean 16.3 million people are "addicted" in the way popular culture understands the term, but it does mean their cannabis use is causing clinically significant impairment or distress — interfering with work, relationships, health, or daily functioning.
One of the underappreciated factors is potency. The average THC concentration in cannabis products has roughly tripled since the year 2000. Flower that once contained 4 to 5 percent THC has been replaced by strains exceeding 20 percent, and concentrates routinely reach 80 to 90 percent. The cannabis your parents tried in college is not the cannabis available at the dispensary down the street. Whether or not you believe marijuana should be legal — and reasonable people disagree — the potency escalation matters for addiction risk.
Legalization itself has not dramatically increased overall use rates among adults, but it has coincided with increased daily use among existing users and a growing normalization that makes it harder for people who are struggling to recognize their use as a problem.
Vaping and Nicotine: The Youth Crisis
Nicotine is sometimes left out of addiction statistics roundups because it does not produce the dramatic overdose headlines that opioids do. That omission is a mistake. By some pharmacological measures, nicotine is the most addictive substance humans consume — more addictive than heroin, cocaine, or alcohol in terms of the speed and reliability with which it produces dependence.
The vaping epidemic among young people has reshaped the nicotine landscape. The CDC reports that more than 2.5 million US middle and high school students currently use e-cigarettes. Many of these products deliver nicotine concentrations far higher than traditional cigarettes, and the flavored formulations are engineered to appeal to young users.
The JUUL settlement — in which the company agreed to pay hundreds of millions to settle lawsuits from states alleging it deliberately marketed to minors — confirmed what public health advocates had been saying for years: the youth vaping epidemic was not an accident. It was a business strategy.
For young people who began vaping in their early teens, the long-term addiction trajectory is still being written. But early data suggests that adolescent nicotine exposure produces deeper and more durable dependence than adult-onset use, and that many teen vapers will carry their addiction into adulthood.
The Treatment Gap: The Most Damning Statistic
Of the 46.3 million Americans with a substance use disorder, only about 10 percent receive any form of treatment. That means roughly 42 million people who meet the clinical criteria for a disorder that can destroy their health, their relationships, and their lives are navigating it without professional help.
The reasons for this gap are well-documented and stubbornly persistent:
- Stigma is the number one barrier. SAMHSA's survey data consistently shows that the most common reason people do not seek treatment is that they are not ready to stop using — but the second most common reason is that they do not want others to find out they have a problem. The shame associated with addiction keeps millions of people suffering in silence.
- Cost is the number two barrier. Even with insurance, residential treatment can cost $10,000 to $30,000 for a 30-day program. Outpatient treatment is more affordable but still out of reach for many. And for the uninsured, the math is simply impossible.
- Wait times compound the problem. For publicly funded treatment programs, wait times of 3 to 6 weeks are common. For someone in crisis, being told to wait a month for help is functionally the same as being told no help is available. Many people who are ready for treatment in the moment they call will not be ready — or alive — when a spot opens up.
The treatment gap is not a failure of individual willpower. It is a failure of infrastructure, funding, and cultural will. We know how to treat substance use disorders. We simply have not built the systems to do it at scale.
Recovery: What Actually Works
The numbers on recovery are more hopeful than the numbers on treatment access — but only if you can get through the door.
Mutual aid participation correlates strongly with sustained recovery. Research on AA and NA shows that active, ongoing participation in peer support groups is associated with significantly better outcomes than treatment alone. The mechanism is not mysterious: regular contact with people who understand your experience, combined with a structured framework for accountability, provides the social scaffolding that willpower alone cannot.
Accountability doubles the odds. Studies on recovery outcomes consistently show that individuals who have at least one accountability relationship — a sponsor, a partner, a therapist, a structured support system — are approximately twice as likely to maintain sobriety at the one-year mark compared to those who attempt recovery in isolation. The presence of someone who checks in, who notices when you are struggling, and who holds you to your commitments is one of the strongest predictors of long-term success.
Medication-assisted treatment is effective for opioid use disorder. NIDA data shows that medications like buprenorphine, methadone, and naltrexone significantly reduce opioid use, overdose deaths, and criminal activity among people with OUD. Despite this evidence, MAT remains stigmatized — even within the recovery community — and is underutilized relative to its effectiveness. Only about 18 percent of people with OUD receive medication-assisted treatment.
Recovery is not a single event. It is a sustained practice that requires support, accountability, and — for many substances — medical intervention. The people who recover are not the ones with the most willpower. They are the ones with the most support.
What These Numbers Mean for You
If you are reading this, you are probably not here for academic interest. Maybe you are concerned about your own substance use. Maybe you are watching someone you love struggle. Maybe you are in recovery and looking for data to validate what you already know from lived experience.
Whatever brought you here, the core message of these statistics is this: you are not alone, and the problem is not you. Addiction is a systemic crisis, and the treatment gap is a systemic failure. The fact that you are seeking information — that you are paying attention — already puts you ahead of the curve.
Be Candid tracks 18 specific substances with targeted detection and coaching. Whether you are working on alcohol, opioids, cannabis, nicotine, or any other substance, the platform provides accountability, pattern recognition, and guided conversation tools designed to bridge the gap between knowing you need support and actually getting it — without the stigma, the wait time, or the cost barrier of traditional treatment.
The statistics say that accountability is one of the most powerful predictors of recovery. Be Candid is built to put that accountability in your hands — on your terms, with the people you trust.